LENZ Therapeutics, Inc. filings document the company’s transition from ophthalmic product development to commercialization of VIZZ (aceclidine ophthalmic solution) 1.44% for presbyopia in adults. Form 8-K disclosures cover financial results, FDA approval and U.S. availability of VIZZ, product launch updates, safety-related communications, and capital-raising activity under an at-the-market sales agreement.
The company’s proxy and governance materials address shareholder voting matters, executive and board governance, material agreements, capital-structure disclosure, and operating and financial results. The filing record also captures regulatory and commercial disclosures tied to VIZZ, including product approval, launch-stage operations, financing transactions, and risk-related information relevant to a pharmaceutical company commercializing an ophthalmic prescription product.
Lenz Therapeutics, Inc. reported that it sold 1,748,634 shares of common stock on October 7, 2025 at a purchase price of $45.75 per share in a block trade to a single investor. The transaction generated gross proceeds of approximately $80,000,000 for the company. The sale was executed under the company’s existing “at the market” Sales Agreement with TD Securities (USA) LLC, dated April 4, 2025, and was completed pursuant to the terms of that agreement.
Versant entities reported insider sales of 224,974 shares of LENZ Therapeutics, Inc. (LENZ) on 09/30/2025. The Form 4 shows multiple sales by related reporting persons (including Versant Venture Capital VI, L.P. and affiliated Versant GP and Vantage entities) executed at weighted-average prices in ranges of $45.00–$45.99, $46.00–$46.99, and $47.00–$47.02. Post-transaction beneficial ownership amounts are disclosed for direct and indirect holdings, with several Versant entities retaining substantial positions (for example, 1,133,842 shares reported as directly owned by one entity and 842,162 shares indirectly held by another). The filing is signed by Max Eisenberg for the Versant reporting entities on 10/02/2025. The footnotes explain that reported prices are weighted averages from multiple transactions and identify the chain of general partners that may share voting and investment power over the disclosed holdings.
LENZ Therapeutics announced that VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop approved in the United States for treating presbyopia in adults, is now available. This medicine is intended to help adults with age-related difficulty focusing on near objects.
LENZ has begun distributing professional product samples nationwide through its sales force to optometrists and ophthalmologists so eye-care professionals can evaluate and introduce VIZZ to patients. Commercial product shipments to consumers will begin in October through an ePharmacy partner and are expected to expand to broad retail pharmacy availability by mid‑Q4 2025.
Versant entities reported multiple sales of LENZ Therapeutics common stock on 09/18/2025. The Form 4 shows a series of dispositions at weighted-average prices of $41.5908 (sales between $41.25 and $42.24) and $43.0038 (sales between $42.25 and $43.24), plus small sales at $43.30.
Reported transactions include direct and indirect sales: for example, 49,479 and 40,907 shares sold directly and 24,370 and 20,148 shares sold indirectly across the two weighted-average-price groups. The filings list 1,224,718; 1,183,811; and related post-transaction beneficial ownership totals for the reporting entities, and note 842,162 shares held indirectly by Versant Vantage II, L.P.
Versant investment funds disclosed holdings and recent sales of LENZ Therapeutics common stock. Multiple Versant entities report beneficial ownership stakes of 1,183,543 shares (4.1%) for Versant VI, 842,162 shares (3.0%) for Versant Vantage II, and 926,691 shares (3.2%) for Versant VII (the latter includes 70,534 shares issuable on a warrant). The filing lists a series of open-market dispositions in August and September 2025 by Versant VI and Versant VII, including sales on August 22, August 25, August 26 and September 18, 2025 that generated aggregate proceeds in the low millions on each date (examples: Versant VI sold 90,654 shares on September 18, 2025 for approximately $3,828,631.71; Versant VII sold 44,650 shares that same date for approximately $1,885,723.80). The Amendment updates Item 5 of the prior Schedule 13D filings and states that only the amended items are changed, leaving prior disclosures unchanged.
Versant entities reported multiple sales of LENZ Therapeutics common stock on August 22, 25 and 26, 2025. The filing lists a series of non-derivative sales totaling 188,094 shares across those dates at weighted-average prices in ranges between $38.50 and $40.8819 per share. The reporting parties include Versant Venture Capital VI, L.P., Versant Venture Capital VII, L.P. and Versant Vantage II, L.P., and related general partner and GP-GP entities. Footnotes state that certain holdings are held indirectly by VVC VI, VVC VII and VV II, and that the reporting entities may be deemed to share voting, investment and dispositive power over those shares. The Form 4 is signed by Max Eisenberg as Chief Operating Officer for the reporting entities.
Amendment No. 7 to a Schedule 13D reports ownership and recent sales of LENZ Therapeutics, Inc. common stock by multiple Versant-related entities. The filing lists Versant Venture Capital VI, L.P. (Versant VI) as holding 1,400,220 shares, representing 4.9% of the outstanding shares (based on 28,522,096 shares reported as of July 24, 2025). Versant Vantage II, L.P. holds 842,162 shares (3.0%). Versant Venture Capital VII, L.P. holds 1,033,412 shares (including a warrant for 70,534 shares), representing 3.6% on an adjusted basis.
The Amendment discloses share sales: on August 15, 2025 Versant VI sold 145,051 shares at $39.50 per share (proceeds ~$5,729,514.50) and Versant VII sold 69,949 shares at $39.50 (proceeds ~$2,762,985.50). On August 18, 2025 Versant VI sold 30,628 shares at a weighted average $38.5611 (proceeds ~$1,181,049.37) and Versant VII sold 15,085 shares at the same weighted average (proceeds ~$581,694.19). The Amendment updates cover-page holdings and clarifies related general partner relationships; other items from the original Schedule 13D remain unchanged.
Versant-affiliated investment vehicles reported multiple sales of LENZ Therapeutics common stock in mid-August 2025. Versant Venture Capital VI, L.P., Versant Venture Capital VII, L.P. and Versant Vantage II, L.P. sold a total of 260,713 shares across transactions dated 08/15/2025 and 08/18/2025 at prices ranging from $38.26 to $39.50 (a weighted average price reported for some sales as $38.5611). After the reported disposals, the filing shows Versant Venture Capital VI beneficially owned 1,430,848 shares (direct) and 977,963 shares (indirect) in related accounts; Versant Vantage II and affiliated entities reported 842,162 shares (indirect). The filing includes customary disclosure of the general partner/GP-GP structure and disclaimers of beneficial ownership except for pecuniary interests.